SLC5A2 and peripheral arterial disease: Genetically proxied SGLT2 inhibition, utilizing six SNPs as instruments for IVW analysis, did not show significant associations with osteomyelitis (OR 1.16, 95% CI 0.04–31.47, p = 0.930), PAD (OR 0.18, 95% CI 0.05–0.64, p = 0.007), lower limb ulcers (OR 0.07, 95% CI 0.006–0.85, p = 0.036), or cellulitis (OR 1.46, 95% CI 0.25–8.43, p = 0.672) (Figure 2).